– FDA approval based on superiority of Gazyva over standard therapy alone, as shown in Phase II NOBILITY and Phase III REGENCY data – – Gazyva is the only anti-CD20 monoclonal antibody to demonstrate ...
Please provide your email address to receive an email when new articles are posted on . There were no serious bacterial infections or hospitalizations due to infection over 12 months among adults ...
The U.S. Food and Drug Administration (FDA) has approved Gazyva® (obinutuzumab), developed by Genentech, as a treatment for adults with lupus nephritis (LN), also known as lupus-related kidney disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results